Parallel session 15.00 - 16.30
Post-innovation Innovation: Platforms for Drug Repurposing
The cross-sector model is the obvious setting for unlocking the full potential of drug molecules, and for fostering innovation beyond the first discovery and invention rounds. In the Netherlands, much of the focus has been on the regulatory aspects of repurposing and repositioning. By contrast, this session will deal with the science and business behind successful repurposing projects. What are the business incentives? What are the elements needed for successful post-innovation innovation? And is this a valid route towards bringing better medicines to patients faster? We will straighten out the definitions; tap in on the experiences of big pharma, NGO and a social enterprise; and hear how you see the future of post-innovation innovation unfolding.
Confirmed speakers & panellists
- Joris Langedijk, PhD - Corporate Counsel, Brabers
- Adrian Freeman, PhD - Emerging Innovations, AstraZeneca
- Jean-Pierre Paccaud, PhD - Director, Business Development and Corporate Strategy, Global Antibiotic R&D Partnership (GARDP)
- Vincent van der Wel, PhD – Project Leader, Fair Medicine Foundation